



BAFNA PHARMACEUTICALS LIMITED

REGD. OFFICE: "BAFNA TOWERS" 299, THAMBU CHETTY STREET, CHENNAI-600 001, INDIA.
PHONE: 044-25267517/25270992/42677555, FAX: 91-44-25231264, Email: info@bafnapharma.com, Website: www.bafnapharma.com
CIN : L24294 TN1995PLC030698

REF/ 253/2022-23

Dated : 28rd September 2022

Corporate Relations Department BSE Limited Floor 25, P. J. Towers, Dalal Street Mumbai – 400 001	Corporate Listing Department National Stock Exchange of India Limited Exchange Plaza, 5th Floor, Bandra - Kurla Complex, Dalal Street, Bandra (E), Mumbai - 400 051. Mumbai - 400 001.
---	--

Dear Sir/ Madam,

Sub: Proposed sale of equity shares of Bafna Pharmaceuticals Limited by SRJR Life Science LLP, through open market sale for achieving minimum public shareholding.

This is further to our letter dated 08.03. 2022.

We wish to Inform you that member of our promoter group, SRJR Life Sciences LLP, has on 20th September, 2022 divested 102542 equity shares of Bafna Pharmaceuticals Limited (the "Company"), constituting 0.43% of the issued and paid-up equity share capital of the Company as at 20th September 2022 through open market sale in accordance with SEBI Circular No. SEBI/HO/CFD/CMD/CIR/P/43/2018 dated February 22, 2018.

Consequent to the aforementioned open market sale, the Company has complied with the minimum public shareholding requirements as mandated under rules 19(2)(b) and 19A(5) with regards to achieving 10% of public shareholding within the stipulated period under the Securities Contracts (Regulation) Rules, 1957 read with regulation 38 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Thanking You,

Yours faithfully,

For Bafna Pharmaceuticals Limited


(Melagiri Sridhar)
Chief Financial Officer.

